The interaction of IGF binding protein-2 (IGFBP-2) with IGF-I and -II has been investigated in solution using nuclear magnetic resonance (NMR) spectroscopy. Chemical shift perturbations in 15 N-and 2 H/ 15 N-labelled IGF-I or -II upon binding to unlabelled thioredoxin-tagged bovine IGFBP-2 (Trx 1-279 IGFBP-2) have been monitored to identify residues involved directly in the binding interaction as well as any affected by conformational changes associated with the interaction. A key step in obtaining high-quality spectra of the complexes was the use of transverse relaxation optimised spectroscopy (TROSY) methods with partially deuterated ligands. Indeed, because the effects of conformational averaging and aggregation are eliminated in IGF-I and -II bound to IGFBP-2, the spectra of the complexes are actually superior to those of the free ligands. Comparison of our results with the crystal structure of the complex between IGF-I and an N-terminal fragment of IGFBP-5 allowed identification of those residues perturbed by the C-domain of IGFBP-2. Other perturbations, such as those of Gly 19 and Asp 20 of IGF-I (and the corresponding residues in IGF-II) -which are located in a reverse turn linking N-domain and C-domain interactive surfaces -are due to local conformational changes in the IGF-I and -II. Our results confirm that the C-domain of IGFBP-2 plays a key role in binding regions of IGF-I and -II that are also involved in binding to the type-1 IGF receptor and thereby blocking ligand binding to this receptor.
Introduction
Insulin-like growth factor binding proteins (IGFBPs) have diverse biological functions, including increasing the circulating half-life of IGFs, delivery of IGFs to target tissues and modulation of IGF interaction with receptors (Clemmons 2001 , Firth & Baxter 2002 . IGF bound to IGFBPs is unable to interact with and activate the type-1 receptor (IGF-1R; Bach et al. 1994) . Essentially all (99%) of the IGFs in the circulation or the extracellular space are associated with one of six IGFBPs (IGFBP-1 to -6) (Frystyk 2004) . However, IGF release from the complex by proteolysis of IGFBPs or their interaction with the extracellular matrix leads to increased availability of IGF to bind to the IGF-1R. IGF activation of the IGF-1R results in cell proliferation, differentiation and survival. These properties are central to the role of IGF-I in disease states including cancer and acromegaly (Denley et al. 2003 , Paisley & Trainer 2003 , Pollak et al. 2004 .
Given the diverse biological effects of IGFs and the central role of IGFBPs in the regulation of IGF activity, the molecular interactions between the IGFs and IGFBPs are of particular interest. High-resolution solution structures have been determined for both IGF-I (Cooke et al. 1991 , Sato et al. 1992 and IGF-II (Terasawa et al. 1994 , Torres et al. 1995 , but not for the IGFBPs. IGF residues involved in binding IGFBPs have been identified using a range of techniques, including residue or domain swapping with insulin and amino acid deletions or mutations (reviewed by Carrick et al. 2002) . Analogue studies have shown the importance of the Band A-domains of the IGFs (Fig. 1 ) in IGFBP binding. Swapping the B-domain of IGF-I for the corresponding insulin B-domain conferred IGFBP binding ability on insulin (De Vroede et al. 1985) , and replacement of the IGF-I B-domain with the insulin B-domain reduced serum IGFBP binding . Glu 3 of IGF-I was shown by site-directed mutagenesis and deletion analyses to contribute to the IGFBP interaction (Bagley et al. 1989) , as does the corresponding residue in IGF-II, Glu 6 (Francis et al. 1993) . IGF-I B-domain residues Gln 15 and Phe 16 are also important, with their mutation, in combination with Glu 3 and Thr 4 to the corresponding insulin residues, decreasing binding to serum IGFBP by up to 600-fold . Alanine scanning mutagenesis across the entire IGF-I molecule identified B-domain residues Gly 7 , Leu 10 and Phe 25 as important for IGFBP-1 interaction (Dubaquie & Lowman 1999) . Mutagenesis of Phe 26 in IGF-II to either Ser or Leu also affected binding to IGFBPs (Bach et al. 1993) as well as the IGF-1R and insulin receptors (Sakano et al. 1991) .
A-domain residues Phe 49 , Arg 50 and Ser 51 of IGF-I , Oh et al. 1993 and Phe 48 , Arg 49 and Ser 50 of IGF-II (Bach et al. 1993) are also important for IGFBP interactions. Alanine substitution of IGF-I A-domain residues Ile 43 , Val 44 or Leu 54 reduced binding to IGFBP-1 by 2-to 4-fold, but had a negligible effect on IGFBP-3 binding (Dubaquie & Lowman 1999) . Indeed, different IGF analogues affect binding to each IGFBP family member to varying degrees , Bach et al. 1993 , Magee et al. 1999 .
The three-dimensional structures of full-length IGFBPs have not yet been determined. The only structural information available until recently has been for residues 40-92 of the N-domain of IGFBP-5, alone (Kalus et al. 1998 ) and in complex with IGF-I (Zesławski et al. 2001) . This region, designated mini-IGFBP-5, binds IGF-I and -II with respectively 10-fold and 80-fold lower affinity than full-length IGFBP-5 (Kalus et al. 1998) . It contains a hydrophobic IGF binding site, with six of the 12 mini-IGFBP-5 residues within 4 Å of IGF-I being hydrophobic, as well as four of the 12 IGF-I residues within 4 Å of mini- IGFBP-5 (Zesławski et al. 2001) (Fig.  1) . We have recently determined the solution structure of the C-domain of IGFBP-6 (Headey et al. 2004a ) and mapped the binding site for this C-domain on IGF-II using NMR (Headey et al. 2004b) . The IGFBP-6 C-domain has a flat, disc-like structure and its binding to IGF-II perturbs a large number of residues on the surface of IGF-II. This surface lies adjacent to and between the binding sites for the IGFBP N-domain and IGF-I receptor, which have previously been found on opposite sides of the IGF molecule. The C-domain is therefore likely to interfere with IGF binding to the IGF-I receptor, providing a structural basis for the potent inhibitory effects of intact IGFBPs on IGF actions (Headey et al. 2004b) .
Despite this progress, we still do not have a clear picture of the interactions of a full-length IGFBP with either of the IGFs. Several years ago, NMR was used to investigate the IGFBP-1 binding surface of IGF-I (Jansson et al. 1998 (Jansson et al. 1998) . The contributions of the Arg residues in IGF-I to IGFBP-1 and IGF-I receptor binding were probed by Ala substitutions, which showed that Arg 50 was important for interaction with IGFBP-1 (Jansson et al. 1998) . However, the IGF-I 15 N and 1 H chemical shift perturbations found in that study were very small (for example, most NH chemical shifts changed by c0·1 p.p.m.), with the largest shift being seen for Ala 70 which is almost certainly not part of the IGFBP-1 binding surface. By contrast, some NH shift perturbations of mini-BP-5 upon IGF-II binding were as large as 2 p.p.m. (Kalus et al. 1998) . In retrospect, it seems likely that the conditions used in the IGF-I/IGFBP-1 study (30 C and pH 3·4), did not favour complex formation and that the small chemical shift differences that were observed arose from a variety of factors.
In this study we have investigated the interactions of bovine IGFBP-2 with both IGF-I and -II by monitoring NMR chemical shift perturbations. Good-quality spectra were obtained for both complexes, allowing the IGFBP-2 binding surfaces of both IGFs to be mapped.
Materials and methods

Protein production
Recombinant human IGF was expressed and purified from Escherichia coli JM101 cells [F' traD36 proAB laclqZ M15]) as described previously (King et al. 1992 , Francis et al. 1993 . Briefly, E. coli containing the IGF expression vectors Figure 1 Amino acid sequences of human IGF-I and -II. In the sequence of IGF-I, residues within 4 Å of mini- BP-5 (Zesławski et al. 2001) are highlighted in bold and those shown to be important for IGF-I receptor binding , Bayne et al. 1990 , Sakano et al. 1991 , Perdue et al. 1994 , Jansson et al. 1998 , Sato et al. 2000 are underlined. In the sequence of IGF-II, residues shown by mutational studies to be involved in IGFBP binding by IGF-I and/or IGF-II are highlighted in bold , Luthi et al. 1992 , Bach et al. 1993 , Francis et al. 1993 , Jansson et al. 1998 , Dubaquie & Lowman 1999 , Sato et al. 2000 . Residues in the C and D regions of the IGFs are shaded.
pGH(1-11)-VN-IGF-I (Francis et al. 1993) , pGH(1-11)-VNPAPH-IGF-II (Lien et al. 2001) or pGH(1-11)-VNFAHY-IGF-II (Francis et al. 1993) were maintained in minimal medium with 60 mM ( 15 NH 4 ) 2 SO 4 as the sole source of nitrogen in 2 l bioreactors (Applikon Bioreactor, Schiedam, Holland) as described by King et al. (1992) 4 . Protein was recovered from inclusion bodies by resuspending in 8 M guanidine HCl followed by desalting on the fast protein liquid chromatograph using a 50 200 mm column packed with Sephadex G-25 M (Pharmacia). IGF-I was released from the fusion partner by hydroxylamine cleavage while IGF-II was cleaved from its fusion partner by either -lytic protease (Lien et al. 2001) or H64A subtilisin (Francis et al. 1993 IGFBP-2 and Trx 1-132IGFBP-2, fusion proteins of full-length bovine IGFBP-2 and the IGFBP-2 N-domain respectively, with thioredoxin, were produced in E. coli BL21 cells as described previously (Carrick et al. 2001) . The thioredoxin fusion protein was removed by cleavage with EkMax enterokinase (Invitrogen) to yield IGFBP. All protein concentrations were determined by reversephase HPLC using Long-[Arg 3 ]-IGF-I (Laajoki et al. 1997 ) as a standard.
Biosensor analysis
Kinetic analyses were performed with IGF-I and -II immobilised to the CM5 gold chip as described by Carrick et al. (2001) . Bovine IGFBP-2 analyte in McIlvaine's citric acid phosphate running buffer (pH 3·4, 4·4, 5·4, 6·4 or 7·4) was passed over the IGF biosensor surfaces equilibrated at the same pH at a flow rate of 40 µl/min. The association and dissociation phases of the interaction were recorded as described previously (Carrick et al. 2001) . Samples were injected in duplicate in random order in at least two separate experiments. IGF biosensor surfaces were regenerated with 10 mM HCl. Analysis of kinetic data was performed with BIAevaluation 3·2 software (Biacore International Ltd, Box Hill, Victoria, Australia). For each binding curve the response obtained using control surfaces (no protein coupled) was subtracted. IGFBP-2 binding fitted a 1:1 Langmuir binding model using global fitting; this model describes a simple reversible interaction of two molecules in a 1:1 complex. Goodness of fit measured as a 2 value was c0·5 for all experiments. All binding experiments were repeated at least in duplicate and biosensor chips coupled at different times yielded surfaces with very similar binding affinities.
Gel filtration
Bovine IGFBP-2 and Trx 1-279 IGFBP were analysed by gel filtration on a Superdex 200 column (Pharmacia) and SMART system (Amersham). Protein samples were loaded on to the column at a concentration of 7·5 mg/ml in phosphate buffer, 150 mM NaCl, pH 6·4, at a flow rate of 40 µl/min and compared with the high molecular mass standards: thyroglobulin (669 kDa), ferritin (440 kDa), human IgG (160 kDa), transferrin (81 kDa), ovalbumin (43 kDa), myoglobin (17·6 kDa) and vitamin B12 (1·4 kDa) (Sigma and Pharmacia). NMR spectra were recorded on Bruker AMX-500 or DRX-600 spectrometers with a probe temperature of 34 C. Spectra were also recorded at 27, 30 and 45 C as indicated. Typically, 512 scans were acquired per increment, with 70-90 t 1 increments and recycle times of 1·8 and 1·4 s for one-and two-dimensional spectra respectively. Final matrix sizes were 2048 and 1024 points in the 1 H and 15 N dimensions respectively. Presaturation or pulsed-field gradients were used to suppress the water resonance (Sklenar et al. 1993) . 1 H sweep widths were 5813·95 and 7122·5 Hz at 500 and 600 MHz respectively. Spectra were processed and analysed on Silicon Graphics workstations using XWINNMR (version 1·3, Bruker) and assigned using XEASY (Bartels et al. 1995) . NMR spectra included: two-dimensional 1 H-15 N HSQC, two-dimensional 1 H- H dimension and indirectly using the experimentally determined frequency ratios for 15 N (0·101 329 118+(T 300 K) 2·74 10 10 ) and 13 C (0·251 449 530+(T 300 K) 1·04 10 9 ), where T is the sample temperature (Wishart et al. 1995) .
A three-dimensional NOESY-TROSY spectrum (Zhu et al. 1998 (Zhu et al. , 1999 
Results
Comparison of IGFBP-2 and Trx
1-279
IGFBP-2 for NMR studies
Trx 1-279 IGFBP-2 and IGFBP-2 interact similarly with IGF-I and -II immobilised on biosensor surfaces at pH 7·4, and the binding kinetics derived using a 1:1 Langmuir binding model are essentially the same (Table 1) . IGFBP-2 exhibits similar biosensor curves at pH 7·4, 6·4 and 5·4, but the dissociation from IGF is slightly faster at pH 4·4 and significantly faster at pH 3·4 (Fig. 2) . Consequently, our NMR studies of the changes in IGF chemical shifts upon binding of IGFBP-2 were conducted at approximately pH 5, where strong binding was observed but self-association of IGF-I and -II (see below) was not so extensive as to prevent the observation of spectra for the free ligands. Our previous BIAcore analyses show that IGFBP-2 and IGF-II form a 1:1 complex (Carrick et al. 2001) , as was also previously established by Bourner et al. (1992) using Scatchard analysis.
The thioredoxin fusion partner contributed to the solubility of proteins during expression in E. coli, and restricted aggregation of the purified protein. The quaternary states of IGFBP-2 and Trx 1-279 IGFBP-2 were analysed at millimolar concentrations by gel filtration. While IGFBP-2 formed large oligomeric aggregates at high protein concentrations and neutral pH, Trx 1-279 IGFBP-2 remained monomeric under identical gel filtration conditions (Fig. 3) .
Spectra of free IGF-I and -II
IGF-I and -II have been difficult to study structurally because they contain regions of high mobility, undergo conformational averaging and aggregate in solution at millimolar concentrations. Because of these problems, IGF-I and -II yield poorer quality NMR spectra at pH values above 3. Sato and co-workers reported an improvement in IGF-I spectral quality upon addition of 10% (Sato et al. 1992) or 20% acetic acid (Sato et al. 1993) , although the same was not true for IGF-II Table 1 Kinetics of the interactions of IGFBP-2 and Trx 1-279 IGFBP-2 with IGF-I and -II using the 1:1 Langmuir binding model
The 1:1 Langmuir binding model was used to fit kinetic data for the interaction between IGFBP-2 and Trx IGFBP-2 across both IGF-I and -II biosensor surfaces at pH 7·4. Association rates (k a ), dissociation rates (k d ), and dissociation constants (K d =k d /k a ) are given. Dissociation constants relative to IGFBP-2 for IGF-I and -II biosensor surfaces are also presented (K d bIGFBP-2/ Trx 1-279 IGFBP-2). The association and dissociation rates are also given relative to IGFBP-2 for IGF-I -II biosensor surfaces. Torres et al. 1995) . Attempts to crystallize IGF have only recently been successful and then only as complexes with other molecules (Vajdos et al. 2001 , Zesławski et al. 2001 .
Before attempting to define the IGFBP binding sites on IGF-I and -II, we recorded a series of twodimensional 1 H- 15 N NMR spectra on the free ligands. Both 15 N-and 2 H/ 15 N-labelled IGF-I and -II were examined. Partial deuteration of the IGF ligands significantly improved the quality of HSQC and TROSY spectra compared with the fully protonated samples. Broad peaks evident in the spectrum of [ 15 N]IGF-I were sharpened significantly upon partial deuteration of the ligand and several additional peaks were observed (see Supplementary Material available at http://www.wehi.edu.au/resources/norton). Furthermore, the TROSY spectrum of [
15 N]IGF-I was much improved over the HSQC spectrum of the equivalent sample recorded at 600 MHz, pH 4·8 and 30 C, although Asn and Gln side-chain resonances were weaker in the TROSY spectra, as expected (Pervushin et al. 1997 , Fernández & Wider 2003 .
Resonance assignments for IGF-I
There are significant differences among chemical shift values reported in the literature for IGF-I (Cooke et al. 1991 , Sato et al. 1992 Cooke et al. (1991) and Sato et al. (1992) are small and probably reflect the different temperatures at which spectra were acquired (50 C (pH 2·9) and 40 C (pH 3) respectively). (Cooke et al. 1991 , Sato et al. 1992 , more so than would be expected for variation in temperature (30 C) and pH (4·1). This was despite the fact that the 13-residue N-terminal extension and mutation of Glu 3 to Arg were reported to have little effect on the secondary structure of IGF-I (Laajoki et al. 1997) NMR experiment and that the free and bound forms were in slow exchange on the NMR time scale (Lian & Roberts 1993) , both of which are consistent with the low nanomolar K d values obtained from biosensor measurements ( Table 1 ). The task of assigning resonances of IGF-I in the complex would have been straightforward had the free and bound forms been in fast exchange, where a single resonance would be observed for each backbone amide at a position determined by the resonance positions in the free and bound states and their relative populations. To explore whether this condition could be achieved at lower pH, where binding affinity is reduced (Fig. 2) , NMR spectra were acquired at 37 C and pH values of 5·1, 3·8, 3·5 and 2·8. At pH 3·8 and 3·5 the complex remained intact, with shifts essentially the same as at pH 5, while at pH 2·8 the spectrum resembled that of the free ligand. Clearly, the binding affinity declined significantly below pH 3·4, but exchange between free and bound IGF-I remained in the slow limit (Lian & Roberts 1993) down to this pH. Apparently IGF-I binding to Trx 1-279 IGFBP-2 in the NMR experiments was stronger than implied by the biosensor data, suggesting that future NMR studies could be carried out at a lower pH, around 4, where the spectra of free IGF-I and -II (see below) were less affected by aggregation.
At 37 C and pH 5·1 a large number of peaks in the TROSY spectrum of IGF-I shifted upon binding to Trx 1-279 IGFBP-2, as shown in Fig. 4A . Assignment of the shifted peaks in the complex was not possible Figure 4A because a three-dimensional NOESY-TROSY spectrum could not be obtained in a reasonable time for this size complex at 0·5 mM. Our interpretation of the spectral perturbations is therefore based on classification of IGF-I peaks as either 'not shifted' relative to free IGF-I, 'shifted' or 'disappeared'. Shifted peaks are defined as those that had moved in one or both of the 1 H and 15 N dimensions but were still close enough to the corresponding peak in free IGF-I to be assignable, for example Cys 18 and Asp 20 in Fig. 4A , while peaks classified as disappeared had moved far enough in the complex that they could not be assigned by comparison with the spectrum of free IGF-I, for example Gly 19 and Leu 54 in Fig. 4A IGFBP-2 (black) Spectra were acquired at 600 MHz and 34°C, at pH 5·1 for free ligands and pH 4·8 for the complexes. Spectra were referenced to an intrinsic peak at 0·15 p.p.m. and overlaid for comparison using XEASY (Bartels et al. 1995) . Note that the TROSY spectra shown in this figure have backbone amide chemical shifts that differ from those in conventional HSQC spectra by approximately +0·7-0·8 p.p.m. in the 15 N dimension and −0·08 p.p.m. in the 1 H dimension, as expected (Pervushin et al. 1997) . A colour version of this figure is available in the Supplementary Material. Fig. 5A . Carrick et al. (2001) demonstrated using BIAcore analysis that high-affinity binding to IGF-I or -II could only be achieved when both the amino-and carboxyl-terminal domains of IGFBP-2 are present and covalently linked. In an attempt to further define the differences between the amino-and carboxyl-terminal binding domains of IGFBP-2, we investigated the interaction of IGF-I with Trx 1-132 IGFBP-2, which contains just the N-domain. Under the solution conditions used for the full-length protein (0·5 mM IGF-I and binding protein), complex formation with the N-domain was incomplete, with the peaks shifted in the complex corresponding to about 20% of the total IGF-I (spectra not shown). Clearly the N-domain binds IGF-I less strongly than full-length IGFBP-2 under these conditions, even though the K d obtained from biosensor measurements (Carrick et al. 2001) would predict nearly 100% complex formation at 0·5 mM. Binding was still tight enough for the free and bound forms to be in slow exchange. Spectra acquired at a lower temperature (27 C) did not significantly influence the proportion of free and bound ligand. Because there was substantial residual intensity for all peaks of the free ligand, it was difficult to determine which peaks that shifted in the complex with full-length protein were not shifted in the presence of the N-domain. However, it was clear that several peaks in the spectrum of the full-length complex were not present in the spectrum of the N-domain complex, for example the cross-peaks at 8·9/119, 8·8/114 and 8·7/120 p.p.m. in Fig. 4 , as well as several peaks from side chains in the region 6·6-7·2 p.p.m. One peak that clearly does not shift in the presence of the N-domain is Gly 19 , indicating that its significant shift in the presence of full-length IGFBP-2 (Fig. 4) arises from interactions with the C-domain.
IGF-I interaction with the N-terminal domain of IGFBP-2
IGF-II assignments
Spectra of IGF-II were less dispersed than those of IGF-I, containing a number of broad signals attributable to aggregation and/or conformational averaging. As reported by Torres et al. (1995) , the presence of broad peaks presents problems with spectral analysis and resonance assignments. TROSY spectra of IGF-II were acquired at 34 C and pH 4·8 and resonances were assigned based on those of Torres et al. (1995) at 27 C and pH 3·1, although the higher pH used in our study caused additional line broadening and therefore greater peak overlap. Our chemical shifts for IGF-II were within 0·06 p.p.m. of reported values (Torres et al. 1995) 
IGF-II interaction with full-length IGFBP-2
As observed for IGF-I, the chemical shift perturbations upon complex formation with Trx 1-279 IGFBP were large, and the free and bound forms were in slow exchange (Fig. 4B) . Therefore assignments for free IGF-II could not be transferred readily to the spectra of complexed IGF-II. It is noteworthy that the quality of the IGF-II spectrum in complex with Trx 1-279 IGFBP-2 is actually better than that of free IGF-II, even though the complex has a mass of 50 kDa and the mass of monomeric IGF-II is 7·5 kDa. The greater dispersion and improved linewidths in the spectrum of the complex indicate that at least some of the flexible and less structured regions of free IGF-II (Torres et al. 1995) appear to be stabilized in the complex, thus enhancing chemical shift dispersion. In addition, non-specific aggregation and/or conformational averaging, which are responsible for broad linewidths in spectra of free IGF-II, largely disappeared after formation of the complex. The quality of the TROSY spectrum of the Trx 1-279 IGFBP-2-IGF-II complex implies that it does not self-associate in solution. A slight improvement in the spectrum of IGF-I was also evident upon complex formation (Fig. 4A) but the effect was less noticeable because free IGF-I is less prone to aggregation. Using the same approach as for IGF-I, we have classified peaks in IGF-II affected by complex formation as 'shifted' or 'disappeared', with the caveat that identification of the peaks in free IGF-II is more difficult because of the broad lines and substantial overlap. 49 and Cys 60 also appear to have shifted but they are partially overlapped with side chain resonances. These residues are highlighted in the sequence of IGF-II in Fig. 5A .
The spectral resolution of IGF-II did not show a significant improvement upon addition of Trx IGFBP-2. Indeed, the increase in effective molecular mass resulted in broadened line widths and reduced spectral resolution compared with that of free IGF-II.
As with IGF-I, it appears that the extent of complex formation in the NMR sample is less than predicted from biosensor data. With a K d for the IGF-II-1-132 IGFBP-2 complex of 51 nM (Carrick et al. 2001) , complex formation should have been largely complete at the 0·5 mM concentrations of ligand and binding protein used for the NMR study, and yet the appearance of the IGF-II spectrum implies that most of it is still free.
Discussion
NMR has been used in this study in order to define the IGFBP-2 binding surfaces of IGF-I and -II. Specifically, chemical shift perturbations in 15 N-and 2 H/ 15 Nlabelled IGF-I or IGF-II upon binding to unlabelled Trx IGFBP have been monitored to identify residues involved directly in the binding interaction as well as any affected by conformational changes associated with the interaction.
Analysis of perturbations of IGF resonances upon complex formation with IGFBP-2 relied on resonance assignments for the free ligands. For both IGF-I and IGF-II, resonance assignments were hampered by the lack of spectral dispersion and broad linewidths, arising from conformational averaging and the tendency of IGF-I (and even more so, IGF-II) to aggregate. Problems due to line broadening have been encountered previously in NMR studies of insulin (Kline & Justice 1990 , Hua & Weiss 1991 , IGF-I (Cooke et al. 1991 , Sato et al. 1992 ) and IGF-II (Terasawa et al. 1994 , Torres et al. 1995 . In this study, deuteration of the ligand and the use of TROSY-based experiments improved spectral quality, particularly of the complexed ligand.
Chemical shift mapping is a quick and effective method for mapping protein interactive surfaces in solution as we demonstrated in our recent study of the interaction of IGF-II with the C-domain of IGFBP-6 (Headey et al. 2004b ). In the current study, changes in backbone amide 1 H and 15 N chemical shifts were used as a monitor of the IGFBP-2 binding surfaces on IGF-I and -II, with peaks classified into three groups according to the size of their shifts. A more quantitative analysis in terms of weighted average shift magnitudes was precluded by the lack of assignments for the bound state and the absence of some resonances in the free state. The lack of assignments for the bound ligands also precluded application of the method of saturation transfer (Takahashi et al. 2000 , Nakanishi et al. 2002 to map the binding interface. In this technique, magnetization is transferred from the larger binding partner, in this case IGFBP-2, to the ligand being observed by NMR. Generally speaking, this approach would provide a more precise picture of the binding surface than that obtained by mapping chemical shift perturbations, which usually identify a larger interaction surface than x-ray crystallographic studies (Huang et al. 1998 , Ding et al. 2000 . Thus, it should be borne in mind in interpreting our results and when comparing our data with the mini-IGFBP-5 surface of IGF-I described by Zesławski et al. (2001) that the actual contact surface between the IGFs and IGFBP-2 is likely to be slightly smaller than inferred from our observed spectral perturbations.
It is unlikely that significant conformational changes occur in IGF-I or -II upon complex formation. Crystal structures have been reported recently for IGF-I in complex with mini- IGFBP-5 (Zesławski et al. 2001 ) and the detergent, deoxy big CHAPS (Vajdos et al. 2001) , and a well-defined solution structure for IGF-I bound to a peptide derived from phage display (Schaffer et al. 2003) . The overall structure of IGF-I observed in solution (Fig. 5B) is preserved in these complexes, although the loops and termini, which are less well defined in the solution structures, generally adopt more ordered structures in the complexes.
The chemical shift perturbations observed in this work for IGF-I and -II upon complex formation with Trx 1-279 IGFBP were significantly greater than those reported by Jansson et al. (1998) for binding of IGF-I to IGFBP-1. It is possible that very little complex between IGF-I and IGFBP-1 was present at pH 3·4, as used by Jansson et al. (1998) , and that the reported chemical shift differences reflect at least partly the influence of pH on the spectrum of free IGF-I. We performed BIAcore analyses of the binding interaction between IGF-I or IGF-II and IGFBP-2 to determine the effect of pH on complex formation. The binding curve at pH 3·4 was atypical of the high-affinity binding interaction with IGFBP-2, showing more rapid dissociation from IGF-I biosensor surfaces than at pH 4·4 or 5·4. Furthermore, TROSY spectra of the complex at various pH values in (Headey et al. 2004b ) are shaded grey. The locations of the three -helices in [43] [44] [45] [46] [47] [48] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [42] [43] [44] [45] [46] [47] [48] [49] (Laajoki et al. 2000) and IGF-II (Torres et al. 1995) are shown in stereo. The backbone is shown as a ribbon and the side chains as lines. The C positions of each fifth residue are numbered. The orientations of the two structures are similar over the well-defined regions; in IGF-I this orients the tip of the poorly defined loop (encompassing the C-domain) towards the viewer whereas in IGF-II it is oriented vertically. Structures were generated in MOLMOL (Koradi et al. 1996) . A colour version of this figure is available in the Supplementary Material. this study indicated that the complex dissociated between pH 3·5 and 2·8.
Not unexpectedly, when we compare the chemical shift differences for IGF-I and -II complexed with IGFBP-2 (highlighted residues in Fig. 5A ), it is clear that the residues affected by IGFBP-2 binding are similar in both cases. This reflects the relatively similar binding affinities ( Table 1) . Some of the differences between the residues highlighted in Fig. 5A for IGF-I and -II reflect problems arising from spectral overlap and broad resonances. For example, Gly 7 and Ala 8 are not visible in our spectra of free IGF-I, while Leu 53 in IGF-II is heavily overlapped with other peaks. Comparing the highlighted residues in Fig. 5A with the 12 IGF-I residues identified by Zesławski et al. (2001) as lying within 4 Å of mini-IGFBP-5 in the crystal structure of the complex (Fig. 1) , the first six (from the IGF-I B-domain) are in close agreement, being either perturbed upon binding to IGFBP-2 or adjacent to residues that are perturbed. There is 63% sequence similarity between mini-IGFBP-5 and the corresponding region of IGFBP-2 so a significant correlation between the two binding sites in this region is expected. The remaining six contact residues occur between Cys 52 and Glu 58 in IGF-I, and chemical shift perturbations with IGFBP-2 are observed for various residues from this region of IGF-I and -II.
There are also some interesting differences between our results and the mini-IGFBP-5 study. In both IGF-I and -II we see significant perturbations in the Gly 22 -Phe 25 region (Fig. 5A ). Mutational analyses have previously shown that Phe 23 -Phe 25 are involved in IGFBP binding by IGF-I or -II , Luthi et al. 1992 , Bach et al. 1993 , Francis et al. 1993 , Dubaquie & Lowman 1999 . These residues are on the opposite face of IGF-I from mini-IGFBP-5, and their perturbations must therefore arise from interaction with the C-domain of IGFBP-2. As Phe 23 -Phe 25 are essential for interaction with the type-1 IGF-I receptor (IGF-1R) , Bayne et al. 1990 , Sakano et al. 1991 , Perdue et al. 1994 , our results imply that the C-domain of IGFBP-2 has a crucial role in blocking the interaction of IGF-I and -II with the IGF-1R. This would account for the relative inability of mini-IGFBP-5, which lacks the C-domain, to completely inhibit IGF-IR-dependent IGF actions (Kalus et al. 1998) . In addition, Glu 46 and Cys 48 -Arg 50 are perturbed in both IGF-I and -II (Fig. 5A ). Again, these are not part of the mini-IGFBP-5 interaction surface of IGF-I and are therefore candidates for interaction with the C-domain of IGFBP-2. Mutations in the Cys 48 -Arg 50 region, highlight these residues as important in IGFBP binding by IGF-I or -II , Luthi et al. 1992 , Bach et al. 1993 , Francis et al. 1993 , Dubaquie & Lowman 1999 . Interestingly, this region overlaps the IGF-II/mannose 6-phosphate receptor binding surface (Sakano et al. 1991) . These results are consistent with recent findings for the C-domain of IGFBP-6 (Headey et al. 2004b) (IGF-I numbering) are perturbed in both IGF-I and -II upon IGFBP-2 binding, even though they are not part of the contact surface in the mini-IGFBP-5-IGF-I crystal structure. Headey et al. (2004b) found that the Gln 18 in IGF-II (equivalent to Gln 15 in IGF-I) was perturbed by interaction with the C-domain of IGFBP-6. A further two residues, Gly 19 and Asp 20 of IGF-I and Gly 22 and Asp 23 of IGF-II, are perturbed in the presence of IGFBP-2 (Fig. 5A ), even though they are not within 4 Å of mini-IGFBP-5 in the structure of Zesławski et al. (2001) . Nor are these residues of IGF-II affected upon interaction with the C-domain of IGFBP-6 in solution (Headey et al. 2004b) , although the preceding residue in IGF-II, Cys 21 , was broadened. These residues are located in a reverse turn in both IGF-I and -II, and it seems likely that their chemical shift perturbations arise from a local conformational change associated with residues in the helix before the turn interacting with the N-domain, or with those after the turn interacting with the C-domain. Mutation of these residues to alanine did not alter binding to IGFBP-1 or IGFBP-3 (Dubaquie & Lowman 1999) which suggests that this is a perturbation specific to IGFBP-2. For Gly 19 in IGF-I at least, we can conclude that its significant shift in the presence of full-length IGFBP-2 arises from interactions with the C-domain as it does not shift in the presence of the N-domain alone.
Gly 42 in IGF-I (Gly 41 in IGF-II), which is slightly shifted in both IGF-I and -II, is on the opposite face of IGF-I from the mini-IGFBP-5 binding surface and was not affected by interaction with the C-domain of IGFBP-6 (Headey et al. 2004b) . Again, its slight shift probably reflects a small local conformational change. In IGF-II, Val 35 undergoes a clear shift. This residue is located in the IGF-II C-domain, which is not thought to interact with IGFBPs, although Val 35 Ala IGF-I has a slightly lower affinity for IGFBP-1 (Dubaquie & Lowman 1999) . Also, both Arg 36 and Arg 37 of IGF-I were slightly perturbed upon binding to IGFBP-1 (Jansson et al. 1998) and their combined mutation to Ala reduced binding affinity to a moderate extent.
In summary, we have obtained good-quality spectra of the complexes of IGF-I and -II with IGFBP-2 and identified residues involved in the binding interfaces. Our results correlate well with those of Zesławski et al. (2001) on the interaction of mini IGFBP-5 with IGF-I but we have identified other residues not seen in the mini-IGFBP-5 study. Some of these coincide with regions identified by mutational analysis (e.g. Cys
48
Arg 50 of IGF-I) as having a role in IGFBP binding, and can therefore most likely be attributed to interaction with the IGFBP-2 C-domain (e.g. Phe 23 -Phe 25 of IGF-I). Others, such as Gly 19 -Asp 20 , are likely to be perturbed as a result of local conformational changes. Our results also correlate well with those of Headey et al. (2004b) , who mapped the IGF-II surface involved in binding the C-domain of IGFBP-6. Further definition of the IGF:IGFBP interaction surfaces will come with the use of saturation transfer methods (Takahashi et al. 2000 , Nakanishi et al. 2002 coupled with stronger magnetic fields and cryogenically cooled probes to provide enhanced spectral sensitivity. Nonetheless, a consistent picture of the IGFBP N-domain and C-domain binding surfaces of IGF-I and -II is already emerging from these studies, giving us a better understanding of the molecular basis for IGFBP modulation of IGF actions.
